Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New biopsy test may predict pancreatic tumor danger

NCT ID NCT06406387

Knowledge-focused Sponsor: Azienda Ospedaliera Universitaria Integrata Verona Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether checking for two proteins, ATRX and DAXX, in biopsy samples can help predict how aggressive non-functional pancreatic neuroendocrine tumors (NF-pNETs) are. Researchers will compare biopsy results with surgical tissue from 100 adults to see if the test can guide treatment decisions. The goal is to improve current grading methods and avoid underestimating tumor risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Jun 2024

Expected to finish

Nov 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a diagnosis of pancreatic neuroendocrine tumors

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Cyto/histologic diagnosis of pNETs * Signed informed consent Exclusion Criteria: * Functional pNETs * Multiple pancreatic nodules * Diagnosis of MEN-1 or Von-Hippel Lindau * Mixed types (e.g., mixed neuroendocrine-acinar/adenocarcinoma) or neuroendocrine carcinomas * Predominantly cystic lesions (more than 50% of the volume). * Metastatic tumors at the time of diagnosis * Known bleeding disorder that cannot be sufficiently corrected with co-fact or fresh frozen plasma * Use of anticoagulants that cannot be discontinued * INR \>1.5 or platelet count \<50.000 * Pregnancy or breastfeeding * Failure to sign the patient's or closest relative's informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-functional pancreatic neuroendocrine tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adenoma, Islet Cell non-functional pancreatic neuroendocrine tumor pancreatic neuroendocrine tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic neuroendocrine tumor

Contacts and locations

Locations

  • University Hospital of Verona

    Verona, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.